ChrysCapital Acquires Majority Stake in Novartis India for Rs 1,450 Crore
Key Insights
Swiss pharmaceutical giant Novartis AG has signed an agreement to sell its 70.68% stake in Novartis India (search) to Indian private equity firm ChrysCapital (search) for approximately Rs 1,450 crore.
The transaction involves multiple acquirers with varying price points, including a primary acquisition at Rs 860.64 per share and secondary acquisitions at Rs 701.25 per share.
This marks ChrysCapital (search)'s first majority investment in the pharmaceutical sector, with the firm planning to use Novartis India (search) as a platform for expanding its domestic pharma portfolio.
Swiss pharmaceutical giant Novartis AG has completed the sale of its majority stake in Novartis India (search) to leading Indian private equity firm ChrysCapital (search), marking a significant shift in ownership for the listed Indian pharmaceutical company. The transaction, valued at approximately Rs 1,450 crore based on current market levels, represents ChrysCapital's first majority investment in India's pharmaceutical sector.
Transaction Structure and Pricing
The deal involves a complex acquisition structure with multiple ChrysCapital (search) entities acquiring different portions of Novartis India (search)'s equity. According to stock exchange disclosures, Acquirer 1 will purchase 56.45% of the equity share capital at Rs 860.64 per share, while Acquirer 2 and Acquirer 3 will acquire 10.32% and 3.91% respectively at Rs 701.25 per share.
The transaction triggers a mandatory open offer to eligible public shareholders at Rs 860.64 per share, managed by investment bank Axis Capital (search) in compliance with Securities and Exchange Board of India (SEBI) regulations. At the close of trading on February 19, Novartis India (search) shares were priced at Rs 830.45, giving the company a market capitalization of Rs 2,050.45 crore.
Strategic Implications for ChrysCapital
This acquisition represents a strategic entry point for ChrysCapital (search) into majority pharmaceutical investments. The private equity firm's existing pharmaceutical portfolio includes minority stakes in Intas Pharma (search), Eris Lifesciences (search), Corona Remedies (search), and La Renon (search). Industry sources indicate that ChrysCapital plans to use Novartis India (search) as a platform to expand its domestic pharmaceutical portfolio.
The deal terms grant ChrysCapital (search) the right to nominate directors to Novartis India (search)'s board, and the company's name may be changed following the transaction, subject to necessary regulatory approvals.
Novartis India's Business Profile
Novartis India (search) operates a diverse pharmaceutical portfolio focused on treating diabetes (search) and chronic neurological, cardiological, and dermatological conditions. The company's product lineup includes the well-known painkiller brand Voveran (search) among its key offerings.
For the fiscal year 2024-25, Novartis India (search) reported revenues of Rs 356.27 crore and net profit of Rs 100.90 crore. However, the company's shares have declined 11.63% over the past six months, reflecting broader market challenges in the pharmaceutical sector.
Market Context and Negotiations
The transaction concludes more than a year of negotiations between the parties. ChrysCapital (search) emerged as the sole remaining bidder after several months of discussions, positioning itself to acquire the controlling stake in the Indian pharmaceutical company.
The completion of this deal reflects ongoing trends in India's pharmaceutical sector, where international companies are reassessing their direct ownership structures while private equity firms seek opportunities in the country's growing healthcare market.